INNOVATION PHARMACEUTICALS INC News

Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024

WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed

GlobeNewswireAug 28, 2023 08:00 ET

Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases

WAKEFIELD, MA, June 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced the United St

GlobeNewswireJun 21, 2023 08:00 ET

Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing

WAKEFIELD, MA, June 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company and minority stakeholder in BT

GlobeNewswireJun 5, 2023 10:00 ET

Short Interest in Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) Expands By 30.3%

Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX – Get Rating) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 620,7

kopsourceApr 19, 2023 16:44 ET

Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications

WAKEFIELD, MA, April 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced publication

GlobeNewswireApr 17, 2023 08:06 ET

Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers

WAKEFIELD, MA, March 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, announced today that based o

GlobeNewswireMar 15, 2023 08:03 ET

Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission

WAKEFIELD, MA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company and minority stakeholder in BT

GlobeNewswireFeb 23, 2023 08:06 ET

Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter Into a Definitive Strategic Development Agreement

Multiyear Development and Support Agreement Lays the Foundation for the Realization of an Advanced Software Suite to Enable Revolutionary Treatments of Epilepsy and Brain Tumors WAKEFIELD, MA, Jan. 0

GlobeNewswireJan 9, 2023 07:35 ET

Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin's Potential for Treating Fungal Keratitis

Additionally, Brilacidin to be Screened by NIH/NIAID to Further Characterize Its Broad-Spectrum Antifungal Activity WAKEFIELD, MA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals

GlobeNewswireDec 13, 2022 07:31 ET

Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family

Regulatory clearance lays key technological and regulatory foundation for BT BeaMedical's vision of revolutionizing treatment options in neurosurgery, oncology, and a wide spectrum of other clinical s

GlobeNewswireNov 28, 2022 09:05 ET

NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy "Game-Changing Breakthrough"

Innovation Pharmaceuticals believes U.K. launch of MRgLITT for refractory focal epilepsy substantiates its investment in advanced laser technology of BT BeaMedical WAKEFIELD, MA, Oct. 26, 2022 (GLOB

GlobeNewswireOct 26, 2022 09:35 ET

Innovation Pharmaceuticals Announces Publication of Scientific Article on the Antifungal Activity of Brilacidin

In pre-clinical studies, Brilacidin shown to synergize with marketed antifungals against pathogenic species of aspergillosis, candidiasis, cryptococcosis and mucormycosis, and further exhibited poten

GlobeNewswireOct 4, 2022 07:35 ET

New In Vitro Data Supporting the Broad-Spectrum Antiviral Activity of Innovation Pharmaceuticals' Brilacidin Presented at 2022 Military Health System Research Symposium

Brilacidin shown to inhibit multiple alphaviruses, the bunyavirus Rift Valley Rift Fever, and Echovirus (a non-enveloped picornavirus)WAKEFIELD, MA / ACCESSWIRE / September 15, 2022 / Innovation Pharm

AccesswireSep 15, 2022 07:35 ET

Innovation Pharmaceuticals' Investment in BT BeaMedical Helping Advance New Surgical Laser Platform

WAKEFIELD, MA / ACCESSWIRE / September 13, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today updated shareholders on recent progress by

AccesswireSep 13, 2022 07:35 ET

Innovation Pharmaceuticals Announces NIH/NIAID-Affiliated Researchers to Evaluate Brilacidin's Treatment Potential Against Monkeypox

WAKEFIELD, MA / ACCESSWIRE / August 5, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today announced that Brilacidin, the Company's defens

AccesswireAug 5, 2022 09:35 ET

Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical's Brilacidin as a Novel Oral Mucositis Drug Candidate

WAKEFIELD, MA / ACCESSWIRE / July 22, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provided an update on the Company's Brilacidin p

AccesswireJul 22, 2022 07:35 ET

Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium

Research was performed by scientists at George Mason University's Center for Infectious Disease Research (formerly NCBID)WAKEFIELD, MA / ACCESSWIRE / June 28, 2022 / Innovation Pharmaceuticals (OTCQB:

AccesswireJun 28, 2022 07:35 ET

Innovation Pharma acquires minority stake in Israeli med-tech company Squalus

Innovation Pharmaceuticals (OTCQB:IPIX) said it acquired a minority stake in Israeli medical device maker Squalus Medical. IPIX said Squalus is developing a novel laser-based thermal ablation technolo

Seeking AlphaJun 15, 2022 11:04 ET

Innovation Pharmaceuticals Acquires Stake in Squalus Medical, Seeks to Reshape Cancer and Epilepsy Treatments Through a New Image Guided Laser-Based Ablation Technology

Innovation Pharmaceuticals acquires a minority ownershipSqualus has invented and is developing a leading-edge image guided surgical laser platform for treating previously inoperable cases of epilepsy

AccesswireJun 15, 2022 10:35 ET

Innovation Pharmaceuticals Analyzing Full Dataset for Its Brilacidin COVID-19 Clinical Trial; Company Evaluating New Pipeline Opportunities for 2022

WAKEFIELD, MA / ACCESSWIRE / December 7, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provides shareholders with perspectives on th

AccesswireDec 7, 2021 07:34 ET